Clinical Trial Update: Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the safety, tolerability and effectiveness of Nuedexta in treating Pseudobulbar Affect; results from the study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia
• Pseudobulbar Affect
• Stroke
• Traumatic Brain Injury

Drugs mentioned

• NUEDEXTA (DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE)

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Pseudobulbar Affect (PBA), Stroke | Phase 4 | Status: COMPLETED | Results posted: 2017-03-15